AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma

NORTH CHICAGO, Ill., Sept. 26, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA)... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, non-Hodgkin's lymphoma

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041647

Source: HSMN NewsFeed - September 26, 2016 Category: Pharmaceuticals Source Type: news